Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Questions linger as Novartis, university look to move past Japan Diovan affair

This article was originally published in Scrip

Executive Summary

The Japanese university at the center of a long-simmering controversy over the integrity of data from clinical studies on the cardiovascular protection benefits of Novartis's antihypertensive Diovan (valsartan) is apparently hoping that a prominent public apology following the release of its formal investigation will draw a line under the affair.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC022122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel